| 摘要 |
<p>The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNαactivity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNαactivity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.</p> |
